| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 8.2 | 3.3 | 1.9 |
| Other income | 2.1 | 0.0 | 0.0 |
| Total income | 10.3 | 3.3 | 1.9 |
| Profit before exceptional items & tax | 2.2 | -2.3 | -0.8 |
| Profit before tax | 2.2 | -2.3 | -0.8 |
| Net profit | 2.2 | -0.6 | -0.8 |
| Operating margin | 21.4% | -69.7% | -42.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | +331.60% |
|---|---|
| Operating profit, year on year | +112.50% |
| Operating profit, quarter on quarter | +104.30% |
BSE results filing, NSE: PARMAX. Figures extracted from the filing.
Parmax Pharma Ltd: key numbers
- Share price
- ₹136.40
- Market cap
- ₹51.03 Cr
- Revenue (annual)
- ₹12.11 Cr
- Net profit (annual)
- ₹-4.16 Cr
- P/E (TTM)
- -42.7×Sector 50.4×
- Promoter holding
- 64.66%+33.86% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Parmax Pharma Ltd
All →Parmax Pharma Other Announcement
Parmax Pharma Ltd filed its quarterly shareholding pattern under Regulation 31. The disclosure reflects changes in promoter status following a previously concluded open offer.
Parmax Pharma Annual General Meeting
Parmax Pharma Ltd will hold its 32nd Annual General Meeting on September 29, 2026. The meeting will address the adoption of financial statements and director appointments.
Parmax Pharma Capital Structure Change
Parmax Pharma's promoters acquired shares via preferential allotment. This filing discloses the acquisition of equity stakes by eleven promoter-related entities.
- Value
- ₹8.32 Cr
Parmax Pharma Capital Structure Change
Promoter group members Dhiren Shah and Sunil Shah acquired 22,80,444 equity shares in Parmax Pharma Ltd. The acquisition occurred via a preferential allotment on August 29, 2026.
Parmax Pharma Q4 FY26 Results: Net Loss of ₹0.6 Cr, Loss Narrows
Parmax Pharma Ltd reported revenue from operations of ₹3.3 Cr (-31.2% YoY) and a net loss of ₹0.6 Cr for Q4 FY26.
- Key figure
- Net loss ₹0.6 Cr